Tianhe’s patent on human peripheral blood stem cells has been granted by United States Patent Office. These autologous stem cells are suitable for the treatment of diabetes, cardiovascular diseases, neurodegenerative diseases, and others.
Tianhe’s international patent on human cord blood stem cells has been granted by European Patent Office. This patent will cover the countries in European Union.
Stem Cell Educator therapy becomes one of the top 3 technologies to practically cure type 1 diabetes among over 300 current clinical trials in the world. Read more on Juvenile Diabetes Cure Alliance website: Exhibit 10 in State of the Cure 2013
To advance Stem Cell Educator Therapy and find a cure for type 1 diabetes, a new clinical trial was initiated in children with type 1 diabetes, in collaboration with Dr.Zhiguang Zhou at the Second Xiangya Hospital of Central South University (Changsha, China) as well as the apheresis team from Terumo BCT (Denver, USA)
Dr.Zhao and his team published the Phase I/II clinical trial data in type 2 diabetes, at the peer review clinical journal BMC Medicine. The clinical data demonstrate the safety and efficacy of Stem Cell Educator therapy for the treatment of type 2 diabetes. Stem Cell Educator therapy opens up new avenues to find a cure for type 1 diabetes and type 2 diabetes.
Stem Cell Educator, as a new Medical Device, has been successfully registered at the United States Food and Drug Administration (FDA).
Report from Juvenile Diabetes Cure Alliance (JDCA): Stem Cell Educator therapy is one of six-leading trials targeting the practical cure of type 1 diabetes (total 332 clinical trials in T1D)
Dr.Zhao and his collaborative team at University of Oviedo, Hospital Universitario Central de Asturias (Spain), have successfully treated the 1st type 1 diabetic patient by using Stem Cell Educator therapy. This is an international multi-center Phase II trial approved by the Ministry of Health in Spain.
In collaboration with Hebei Medical University, Tianhe starts a new clinical trial in an autoimmune-related skin disease, titled "Stem Cell Educator Therapy in Alopecia Areata".
The Ministry of Health in Spain has approved the Phase II clinical trial of Stem Cell Educator therapy in type 1 diabetes.